


Hepatitis B

Awareness and Treatment



Epidemiology

Natural History

Therapy

Daryl T.-Y. Lau, MD, MPH


Associate Professor of Medicine

Director of Translational Liver Research

Division of Gastroenterology


BIDMC, Harvard Medical School

Geographic Prevalence of Chronic Hepatitis B Impacted by Migration




Immigration numbers summed by continent from 1996-2002

HBV : Major cause of cirrhosis and liver cancer globally




Therapy for Hepatitis B

Timeline based on FDA Approval in the United States




Time to Disease Progression

Lamivudine vs. Placebo for HBV pts with advanced fibrosis



Time to Diagnosis of HCC


Lamivudine vs. Placebo for HBV pts with advanced fibrosis



Significant Reduction in Cumulative Incidence of HCC with Antiviral Therapy

Cumulative incidence of HCC

(Study with a retrospective US cohort and a Taiwanese REVEAL-HBV cohort)¹



REVEAL, Risk Evaluation of Viral Load Elevation and Associated Liver Disease

A study that included a retrospective US cohort (N=2255 patients with CHB of whom 973 received antiviral treatment) and the community-based Taiwanese REVEAL-HBV study cohort (N=3653; 1991-2014).

Figure adapted with permission from Lin d., et al.

1. Lin D, et al. *Ailment Pharmacol Ther.* 2016;44:846-855. 2. Terrault NA., et al. *Hepatology.* 2016;63:261-283.